Therefore, the most lethal form of breast cancer remains a clinical challenge, despite converging preclinical evidence demonstrating the efficacy of AXL/TAM inhibitors combined with PD-1 blockade in TNBC models. This evidence concerns the gene AXL and breast cancer.